We traveled quite a journey on this front, including an ODAC meeting in March to advise FDA on our supplemental BLA.

May 8, 2024 / CEO / receipt, needs a key / Chip Baird, CEO | earnings call 2024-05-08 | transcript c8a9caed-afe1-461a-8bf5-1377c1660482 | chars 3523-3639 | segment 3

From a site flipping perspective, as we've described before, we continue to increase the number of sites where a Beckman is available for patients in a large market like the U.S. That's really important for patients, particularly later line patients for whom extended travel is difficult. So, again, we started in larger sites. cities and larger academic centers where the catchment was just larger and that made a lot of sense. But as we've increased the footprint, that's going to make Beckman available for more and more patients. And we have plans to continue to expand that footprint over time. So that's an important commercial driver, but I think the main one is going to be our ability to describe and articulate both the The safety profile and the competitive efficacy profile of APECMA in the third line plus setting.

Mar 5, 2024 / CEO / receipt, needs a key / Chip Baird, CEO | earnings call 2024-03-05 | transcript f7c4dfd8-6a37-4a60-9b19-e7af5a233314 | chars 13133-13960 | segment 13